Strong Buy
Immunosyn comprises the platform technology for what many believes may lead to a new, world class series of Biological Response Modifiers (BMRs) developed from mammalian serum. This technology represents a cutting edge scientific breakthrough, utilizing some of the many complex compounds and cells generated by the immune systems of living animals in response to viral, bacterial and other stress challenges. The current research medications for a number of neurological conditions, as derived has demonstrated their ability to create a wide variety of immune responses by targeting both the innate and adaptive immune systems simultaneously.
The basic technology and mechanism of action was originally discovered by Argyll Biotechnologies’ principal investigator, Professor Kenneth Willeford, of Mississippi State University. Claims in a key patent application, which encompass the molecule and names Dr. Willeford as an inventor, have recently been allowed and are expected to issue. Additional patent protection has also been applied for concerning the manufacturing processes and chemical variations for Immunosyn.
In various pre-clinical human studies, performed under either informed consent (EU) or compassionate waiver (U.S.), over 1000 subcutaneous 1.5 ml doses have been administered to over 80 patients, with no major adverse events being reported over a period in excess of 18 months. Treatment with SF-1019 would appear to induce an immunomodulatory cascade, which could explain the therapeutic effects. Patients who were suffering from a range of conditions of the nervous and immune systems, have reported a rapid reduction of their symptoms in as little as 5-6 minutes. Since some of the improvements occur too quickly for known anti-inflammatory pathways, it is possible that SF-1019 possesses neuro restorative properties via a channel blocking process. Moreover, increased levels of cytokine expression were also observed. The immunological profile of patients with inflammatory conditions who have received treatment appear to have had their cytokine profiles convert from a TH-1 to a TH-2 status; in other words, from a hyper-stimulated and pro-inflammatory to a largely anti-inflammatory condition. This would result in the reduction of inflammation mediated tissue damage in patients with such conditions.
